We have located links that may give you full text access.
B7-H3-targeted 212 Pb radioimmunotherapy of ovarian cancer in preclinical models.
Nuclear Medicine and Biology 2017 April
INTRODUCTION: Novel therapies that effectively kill both differentiated cancer cells and cancer initiating cells (CICs), which are implicated in causing chemotherapy-resistance and disease recurrence, are needed to reduce the morbidity and mortality of ovarian cancer. These studies used monoclonal antibody (mAb) 376.96, which recognizes a B7-H3 epitope expressed on ovarian cancer cells and CICs, as a carrier molecule for targeted α-particle radioimmunotherapy (RIT) in preclinical models of human ovarian cancer.
METHODS: mAb 376.96 was conjugated to the chelate 2-(4-isothiocyanotobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoylmethyl)-cyclododecane (TCMC) and radiolabeled with 212 Pb, a source of α-particles. In vitro Scatchard assays determined the specific binding of 212 Pb-376.96 to adherent differentiated or non-adherent CIC-enriched ES-2 and A2780cp20 ovarian cancer cells. Adherent ovarian cancer cells and non-adherent CIC-enriched tumorspheres treated in vitro with 212 Pb-376.96 or the irrelevant isotype-matched 212 Pb-F3-C25 were assessed for clonogenic survival. Mice bearing i.p. ES-2 or A2780cp20 xenografts were injected i.p. with 0.17-0.70MBq 212 Pb-376.96 or 212 Pb-F3-C25 and were used for in vivo imaging, ex vivo biodistribution, and therapeutic survival studies.
RESULTS: 212 Pb-376.96 was obtained in high yield and purity (>98%); Kd values ranged from 10.6-26.6nM for ovarian cancer cells, with 104 -105 binding sites/cell. 212 Pb-376.96 inhibited the clonogenic survival of ovarian cancer cells up to 40 times more effectively than isotype-matched control 212 Pb-F3-C25; combining 212 Pb-376.96 with carboplatin significantly decreased clonogenic survival compared to either agent alone. In vivo imaging and biodistribution analysis 24h after i.p. injection of 212 Pb-376.96 showed high peritoneal retention and tumor tissue accumulation (28.7% ID/g in ES-2 ascites, 73.1% ID/g in A2780cp20 tumors); normal tissues showed lower and comparable uptake for 212 Pb-376.96 and 212 Pb-F3-C25. Tumor-bearing mice treated with 212 Pb-376.96 alone or combined with carboplatin survived 2-3 times longer than mice treated with 212 Pb-F3-C25 or non-treated controls.
CONCLUSION: These results support additional RIT studies with 212 Pb-376.96 for future evaluation in patients with ovarian cancer.
METHODS: mAb 376.96 was conjugated to the chelate 2-(4-isothiocyanotobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoylmethyl)-cyclododecane (TCMC) and radiolabeled with 212 Pb, a source of α-particles. In vitro Scatchard assays determined the specific binding of 212 Pb-376.96 to adherent differentiated or non-adherent CIC-enriched ES-2 and A2780cp20 ovarian cancer cells. Adherent ovarian cancer cells and non-adherent CIC-enriched tumorspheres treated in vitro with 212 Pb-376.96 or the irrelevant isotype-matched 212 Pb-F3-C25 were assessed for clonogenic survival. Mice bearing i.p. ES-2 or A2780cp20 xenografts were injected i.p. with 0.17-0.70MBq 212 Pb-376.96 or 212 Pb-F3-C25 and were used for in vivo imaging, ex vivo biodistribution, and therapeutic survival studies.
RESULTS: 212 Pb-376.96 was obtained in high yield and purity (>98%); Kd values ranged from 10.6-26.6nM for ovarian cancer cells, with 104 -105 binding sites/cell. 212 Pb-376.96 inhibited the clonogenic survival of ovarian cancer cells up to 40 times more effectively than isotype-matched control 212 Pb-F3-C25; combining 212 Pb-376.96 with carboplatin significantly decreased clonogenic survival compared to either agent alone. In vivo imaging and biodistribution analysis 24h after i.p. injection of 212 Pb-376.96 showed high peritoneal retention and tumor tissue accumulation (28.7% ID/g in ES-2 ascites, 73.1% ID/g in A2780cp20 tumors); normal tissues showed lower and comparable uptake for 212 Pb-376.96 and 212 Pb-F3-C25. Tumor-bearing mice treated with 212 Pb-376.96 alone or combined with carboplatin survived 2-3 times longer than mice treated with 212 Pb-F3-C25 or non-treated controls.
CONCLUSION: These results support additional RIT studies with 212 Pb-376.96 for future evaluation in patients with ovarian cancer.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app